GSK-444563/007 (rota-007)

Study to assess efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus vaccine at different viral concentrations in healthy infants previously uninfected with human rotavirus and approximately 3 months of age
Hepatitis B Vaccine, Recombinant
444563/007 (rota-007)
Hepatitis B
Phase 2
An annotated case report form is not available for this study. A blank case report form will be provided.
June 2015